At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02410 TYK MEDICINES-B
Not Yet Opened 04-22 16:08:28
10.360
-0.270
-2.54%
High10.660
Low10.360
Vol1.59M
Open10.660
D1 Closing10.630
Amplitude2.82%
Mkt Cap3.94B
Tradable Cap3.89B
Total Shares380.07M
T/O16.53M
T/O Rate0.42%
Tradable Shares375.46M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
TYK MEDICINES-B's (02410) Self-Developed TY-3002 Monotherapy Demonstrates Outstanding Weight Loss Efficacy, Pioneering Next-Generation Oral GLP-1R Small Molecule Innovation
TYK Medicines Inc is a China-based company mainly engaged in developing and commercializing pharmaceutical products. The Company is primarily focused on small molecule drug development, and its main products include TY-9591, TY-302 and TY-2136. TY-9591 is a third-generation EGFR-TKI with antitumor effects on EGFR mutations. TY-302 is a potent, selective oral CDK4/6 inhibitor developed for the treatment of advanced solid tumors, including breast cancer and prostate cancer. TY-2136b is an internally developed, oral ROS1/NTRK inhibitor for the treatment of solid tumors.